vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v12i5.803vsp-285Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEИММУНОМОДУЛИРУЮЩЕЕ И ЛЕЧЕБНОЕ ДЕЙСТВИЕ БИФИДО- И ЛАКТОБАКТЕРИЙ У ДЕТЕЙ С АЛЛЕРГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ И ЧАСТЫМИ РЕСПИРАТОРНЫМИ ИНФЕКЦИЯМИIMMUNOMODULATORY AND THERAPEUTIC ACTIVITY OF BIFIDO- AND LACTOBACTERIA IN CHILDREN WITH ALLERGIC DISEASES AND FREQUENT RESPIRATORY TRACT INFECTIONSХорошиловаН. В.KhoroshilovaN. V.

Khoroshilova Nataliya Viktorovna, Associate Professor of Clinical Immunology and Allergology

immuno1@rambler.ruФедеральное медико-биологическое агентство, МоскваРоссияFederal Medico-Biological Agency, MoscowRussian Federation201319092013125Вопросы современной педиатрии8689Copyright © Хорошилова Н.В., 20132013Хорошилова Н.В.Khoroshilova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/285

 

Recently probiotics have attracted more and more attention of clinicians and researchers. According to the results of numerous studies, these agents are effective in treatment of acute and chronic diseases of the gastro-intestinal system, and possibility of usage of such drugs in patients with allergic disorders and frequent respiratory tract infections is under active investigation. This review contains data on bifido- and lactobacteria usage in patients with the above-mentioned conditions. It was shown, that lactobacteria have little effect in prophylaxis and treatment of allergic diseases in infants younger 1 year of life, while their efficacy was observed in older patients. According to the results of clinical trials, probiotics with bifido- and lactobacteria decrease the frequency and severity of respiratory infections. Frequently and protractedly ill children are characterized by persistent combined viral-bacterial and viral-bacterial-fungal associations resistant to therapy. In the experimental studies it was established, that species and cultures of lacto- and bifidobacteria including into the composition of a new combined probiotic drug have antagonistic action to conditionally pathogenic causative agents, restore integrity of the intestinal epithelium and increase cytokine production by the immunocompetent cells. Moreover, there are data on antiviral action of lactobacteria. All these makes the above-mentioned combined probiotic a promising drug for complex therapy of frequently and protractedly ill patients with mixed infections.

пробиотикииммунная системачастые респираторные инфекцииаллергологическая патологияprobioticsimmune systemfrequent respiratory tract infectionsallergic diseasesReferencesShenderov B. A. Meditsinskaya Mikrobnaya Ekologiya i Funktsional'noe Pitanie [Medical Microbial Ecology and Functional Nutrition]. In 3 volumes. М. 2001.Shenderov B. A. Meditsinskaya Mikrobnaya Ekologiya i Funktsional'noe Pitanie [Medical Microbial Ecology and Functional Nutrition]. In 3 volumes. М. 2001.Khoroshilova N. V. Immunomoduliruyushchee i Lechebnoe Deystvie Probiotikov [Immunomodulatory and Therapeutic Effect of Probiotics]. Immunologiya [Immunology]. 2003; 24 (6): 352–356.Khoroshilova N. V. Immunomoduliruyushchee i Lechebnoe Deystvie Probiotikov [Immunomodulatory and Therapeutic Effect of Probiotics]. Immunologiya [Immunology]. 2003; 24 (6): 352–356.Hatakka K., Savilahti E. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double-blind, randomised trial. BMJ. 2001; 322: 1327.Hatakka K., Savilahti E. et al. Effect of long term consumption of probiotic milk on infections in children attending day care centers: double-blind, randomised trial. BMJ. 2001; 322: 1327.Rerksuppaphol S., Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr. Int. 2012; 54 (5): 682–687.Rerksuppaphol S., Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr. Int. 2012; 54 (5): 682–687.Fedotova Т. A. Immunnaya Nedostatochnost' u Detey. Rol' Disbakterioza Kishechnika [Immune Deficiency in Children. The Role of Intestinal Dysbiosis]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. Moscow, 1999.Fedotova Т. A. Immunnaya Nedostatochnost' u Detey. Rol' Disbakterioza Kishechnika [Immune Deficiency in Children. The Role of Intestinal Dysbiosis]. Avtoreferat-dissertatsiya kandidata meditsinskikh nauk [Autoabstract-thesis of Candidate of Medical Sciences]. Moscow, 1999.Blyakher М. S., Lopatina Т. K., Zhukova V. M. Vliyanie Probiotikov na Produktsiyu Interferonov i Limfokinov. Probioticheskie Mikroorganizmy — Sovremennoe Sostoyanie Voprosa i Perspektivy Ispol'zovaniya: Materialy Konferentsii [The Effect of Probiotics on the Production of Interferons and Lymphokines. Probiotic Microorganisms: The Present State and Prospects of Use. Proceedings of the Conference]. Moscow, 2002. 29 p.Blyakher М. S., Lopatina Т. K., Zhukova V. M. Vliyanie Probiotikov na Produktsiyu Interferonov i Limfokinov. Probioticheskie Mikroorganizmy — Sovremennoe Sostoyanie Voprosa i Perspektivy Ispol'zovaniya: Materialy Konferentsii [The Effect of Probiotics on the Production of Interferons and Lymphokines. Probiotic Microorganisms: The Present State and Prospects of Use. Proceedings of the Conference]. Moscow, 2002. 29 p.Kalliomaki M., Salminen S., Arvilommi H. et al. Probiotics in primary prevention of atopic disease: a randomized placebocontrolled trial. Lancet. 2001, 357 (9262): 1076–1079.Kalliomaki M., Salminen S., Arvilommi H. et al. Probiotics in primary prevention of atopic disease: a randomized placebocontrolled trial. Lancet. 2001, 357 (9262): 1076–1079.Weston S., Halbut A., Richmond P. et al. Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch. Dis. Child. 2005; 90 (9): 892–897.Weston S., Halbut A., Richmond P. et al. Effects of probiotics on atopic dermatitis: a randomized controlled trial. Arch. Dis. Child. 2005; 90 (9): 892–897.Brouwer M. L., Wolt-Plomen S. A., Dubois A. E. et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebocontrolled trial. Clin. Exp. Allergy. 2006; 36 (7): 899–906.Brouwer M. L., Wolt-Plomen S. A., Dubois A. E. et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebocontrolled trial. Clin. Exp. Allergy. 2006; 36 (7): 899–906.Abrahamsson T. R., Jakobsson T., Bottcher M. F. et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized placebo-controlled trial. Allergy Clin. Immunol. 2007; 119 (5): 1174–1180.Abrahamsson T. R., Jakobsson T., Bottcher M. F. et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized placebo-controlled trial. Allergy Clin. Immunol. 2007; 119 (5): 1174–1180.Kopp M. V., Hennemuth I., Heinzmann A., Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008; 121 (4): 850–856.Kopp M. V., Hennemuth I., Heinzmann A., Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics. 2008; 121 (4): 850–856.Huurre A., Laitinen K., Rautava S. et al. Impact of maternal atopy and probiotics supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin. Exp. Allergy. 2008; 38: 1342–1348.Huurre A., Laitinen K., Rautava S. et al. Impact of maternal atopy and probiotics supplementation during pregnancy on infant sensitization: a double-blind placebo-controlled study. Clin. Exp. Allergy. 2008; 38: 1342–1348.Soh S. E., Aw M., Gerez Y. S. et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants-effects on eczema and atopic sensitization at the age of 1 year. Clin. Exp. Allergy. 2008.Soh S. E., Aw M., Gerez Y. S. et al. Probiotic supplementation in the first 6 months of life in at risk Asian infants-effects on eczema and atopic sensitization at the age of 1 year. Clin. Exp. Allergy. 2008.Taylor A. L., Dunstan J. A., Prescott S. L. Probiotic supple mentation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in highrisk children: a randomized controlled trial. J. Allergy Clin. Immunol. 2007; 19 (1): 184–191.Taylor A. L., Dunstan J. A., Prescott S. L. Probiotic supple mentation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in highrisk children: a randomized controlled trial. J. Allergy Clin. Immunol. 2007; 19 (1): 184–191.Gruber C., Wendt M., Sulser C. et al. Randomized, placebocontrolled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy. 2007; 62 (11): 1270–1276.Gruber C., Wendt M., Sulser C. et al. Randomized, placebocontrolled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy. 2007; 62 (11): 1270–1276.Rosenfeldt V., Benfeldt E., Nielson S. D. et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. Allergy Clin. Immunol. 2003; 112 (2): 389–395.Rosenfeldt V., Benfeldt E., Nielson S. D. et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. Allergy Clin. Immunol. 2003; 112 (2): 389–395.Passeron T., Lacour J. P., Fontas E., Ortonne J. P. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy. 2006; 61 (4): 431–437.Passeron T., Lacour J. P., Fontas E., Ortonne J. P. Prebiotics and synbiotics: two promising approaches for the treatment of atopic dermatitis in children above 2 years. Allergy. 2006; 61 (4): 431–437.Giovannini M., Agostoni C., Riva E. et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr. Res. 2007; 62 (2): 215–220.Giovannini M., Agostoni C., Riva E. et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr. Res. 2007; 62 (2): 215–220.Pelto L., Isolauri E., Lilius E. M. et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milkhypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin. Exp. Allergy. 1998; 28 (12): 1474–1479.Pelto L., Isolauri E., Lilius E. M. et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milkhypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin. Exp. Allergy. 1998; 28 (12): 1474–1479.Isolauri E., Arvola T., Sutas Y. et al. Probiotics in the management of atopic eczema. Clin. Exp. Allergy. 2000; 30 (11): 1604–1610.Isolauri E., Arvola T., Sutas Y. et al. Probiotics in the management of atopic eczema. Clin. Exp. Allergy. 2000; 30 (11): 1604–1610.Rautava S., Isolauri E. The development of gut immune responses and gut microbiota: effects of probiotics in prevention and treatment of allergic disease. Сurr. Iss. Intest. Microbiol. 2002; 3 (1): 15–22.Rautava S., Isolauri E. The development of gut immune responses and gut microbiota: effects of probiotics in prevention and treatment of allergic disease. Сurr. Iss. Intest. Microbiol. 2002; 3 (1): 15–22.Сonti C., Malacrino C., Mastromarino P. Inhibition of Herpes simplex virus type2 by vaginal lactobacilli. J. Physiol. Pharmacol. 2009; 60 (Suppl. 6): 19–26.Сonti C., Malacrino C., Mastromarino P. Inhibition of Herpes simplex virus type2 by vaginal lactobacilli. J. Physiol. Pharmacol. 2009; 60 (Suppl. 6): 19–26.Hori T., Kiyoshima J., Shida K. et al. Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus strain Shirota. Clin. Diagn. Lab. Immunol. 2002; 9: 105–108.Hori T., Kiyoshima J., Shida K. et al. Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus strain Shirota. Clin. Diagn. Lab. Immunol. 2002; 9: 105–108.Kawase M., He F., Kubota A., Yoda K., Miyazawa K., Hiramatsu M. Heat-killed Lactobacillus gasseri TM0356 protects mice against inf luenza virus infection by stimulation gut and respiratory immune response. FEMS Immunol. Med. Microbiol. 2012; 64 (2): 280–288.Kawase M., He F., Kubota A., Yoda K., Miyazawa K., Hiramatsu M. Heat-killed Lactobacillus gasseri TM0356 protects mice against inf luenza virus infection by stimulation gut and respiratory immune response. FEMS Immunol. Med. Microbiol. 2012; 64 (2): 280–288.Villena J., Chiba E., Tomosada Y. et al. Orally administrated Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly (I: C). BMC Immunol. 2012; 13: 53.Villena J., Chiba E., Tomosada Y. et al. Orally administrated Lactobacillus rhamnosus modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly (I: C). BMC Immunol. 2012; 13: 53.Timmerman H. M., Koning C. J. M., Mulder L. et al. Monostrein, multistrein and multispecies probiotics. Int. J. Food Microbiol. 2004; 96: 219–233. 27. Winclove probiotics. Strain information. Document of Winclove b. v. 2012.Timmerman H. M., Koning C. J. M., Mulder L. et al. Monostrein, multistrein and multispecies probiotics. Int. J. Food Microbiol. 2004; 96: 219–233. 27. Winclove probiotics. Strain information. Document of Winclove b. v. 2012.

The authors declare that there are no conflicts of interest present.